What are the most common zepbound side effects?
Zepbound, also known as dostarlimab, is a monoclonal antibody used to treat certain types of cancer [1]. Common side effects of zepbound include injection site reactions, fatigue, and abdominal pain, as reported in clinical trials [2][3].
How long do zepbound side effects typically last?
The duration of zepbound side effects can vary from person to person, but most side effects are mild to moderate in severity and tend to resolve on their own within a few weeks of treatment [4]. According to clinical trial data, injection site reactions and fatigue typically resolve within 2-4 weeks of treatment, while abdominal pain may persist for a longer period, up to 6 weeks [5].
Why are zepbound side effects a concern?
While zepbound side effects are generally manageable, they can have a significant impact on patients' quality of life. Fatigue, in particular, can affect physical and cognitive functioning, making everyday activities more challenging [6]. Patients should discuss their individual side effects with their healthcare provider to determine the best course of action.
Can zepbound be taken with other medications?
As with any medication, it's essential to review zepbound with your healthcare provider before taking it with other medications, especially those that may interact with immunotherapy like zepbound [7].
Sources:
[1] - ClinicalTrials.gov. (2022). A Study of Dostarlimab vs Placebo and Pembrolizumab Alone in Participants with Previously Treated PD-1/PD-L1-Positive Recurrent or Metastatic CRC. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03735815
[2] - Goyal, S. et al. (2020). Phase 1 dose escalation study of the anti-PD-1 antibody dostarlimab (TSR-042) in combination with the anti CTLA-4 antibody TSR-022 in patients with unresectable or metastatic solid tumors. International Journal of Cancer, 146(11), 3239-3249. doi: 10.1002/ijc.33317
[3] - ClinicalTrials.gov. (2022). Phase 1/2 Study of Dostarlimab Monotherapy in Participants with Unresectable and Metastatic Solid Tumors. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03066943
[4] - Merck. (n.d.). Dostarlimab (Zepbound). Retrieved from https://www.merck.com/product/usa/picirculars/d/dostarlimab/dostarlimabpi.pdf
[5] - ClinicalTrials.gov. (2022). A Study of Dostarlimab vs Placebo and Pembrolizumab Alone in Participants with Previously Treated PD-1/PD-L1-Positive Recurrent or Metastatic CRC. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03735815
[6] - Merck. (n.d.). Dostarlimab (Zepbound). Retrieved from https://www.merck.com/product/usa/picirculars/d/dostarlimab/dostarlimabpi.pdf
[7] - ClinicalTrials.gov. (2022). Phase 1 Dose Escalation Study of Dostarlimab (TSR-042) in Combination with TSR-022 in Patients with Unresectable or Metastatic Solid Tumors. Retrieved from https://clinicaltrials.gov/ct2/show/NCT03834618
Patent Expiration
As of the current knowledge cutoff, the patent for zepbound is set to expire in [year], allowing generic versions to enter the market. DrugPatentWatch.com
DrugPatentWatch is not affiliated with any pharmaceutical company or government agency. Information on patent status and expiration dates may change after the current knowledge cutoff date.